haematology
Blood cancers

MM management in Australia lags behind other countries due to reimbursement model

Australian patients with multiple myeloma face critical shortcomings in genetic testing at diagnosis and access to new ‘standard of care’ treatments such as daratumumab, a leading haematologist has told a Parliamentary inquiry. Professor Andrew Spencer of Monash University says the current reimbursement model is unsuited to handling applications for the latest multi-agent anti-cancer treatments and ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic